Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
about
The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structurePyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitroWild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidineCryptoporus volvatus extract inhibits influenza virus replication in vitro and in vivoCryptoporus volvatus extract inhibits porcine reproductive and respiratory syndrome virus (PRRSV) in vitro and in vivoIn search of a selective antiviral chemotherapy.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase.Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptaseTyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine.Screening of selected plant extracts for in vitro inhibitory activity on human immunodeficiency virus.Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
P2860
Q24534107-EB5287F8-FAFE-4F45-9BA8-F4202F4E54BDQ28376481-2194915C-5650-4FD0-8274-851CAEDE3AF5Q33700962-844A805B-499E-43B8-BCC1-DAE6130C4719Q33743954-CC17BEB7-8882-48F4-90BA-AF78EA8C54E7Q33782815-AC3F232E-7687-48B5-B1FC-5817E35774E1Q33808236-30FB2989-9120-4E3D-9B1C-000B3E8425FCQ34600066-7529FA20-4BF0-4A8E-8067-647BB68ADB36Q34737670-ED2047E7-A116-4507-A5BC-C1DC84AED5F9Q35375912-87BF66AD-F88B-4160-B066-56405037D294Q36246775-C44ABBAE-A1DE-40BE-A82B-810AF2215406Q36275612-F7FDF169-5D94-47C2-A8C0-A911B3B9C32CQ39720877-F1F8A4F3-04DD-4BB2-9C1C-7928CCDB517CQ39785298-B0A8CF31-0534-4699-9869-24403AA178ADQ41864362-C5FAC1B9-055A-4563-BB3A-6D09A8B3243DQ44141639-0081BF12-0432-4869-9220-26827DA618FCQ46450181-C3A37984-C3D0-4EAD-87F8-E797373FEF65
P2860
Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Concomitant combination therap ...... erse transcriptase inhibitors.
@ast
Concomitant combination therap ...... erse transcriptase inhibitors.
@en
type
label
Concomitant combination therap ...... erse transcriptase inhibitors.
@ast
Concomitant combination therap ...... erse transcriptase inhibitors.
@en
prefLabel
Concomitant combination therap ...... erse transcriptase inhibitors.
@ast
Concomitant combination therap ...... erse transcriptase inhibitors.
@en
P2093
P2860
P356
P1476
Concomitant combination therap ...... erse transcriptase inhibitors.
@en
P2093
Balzarini J
De ClercQ E
Pelemans H
P2860
P304
13152-13157
P356
10.1073/PNAS.93.23.13152
P407
P577
1996-11-01T00:00:00Z